Aquestive reiterates Q1 2025 NDA filing for Anaphylm; notes FDA approval of non-injection epinephrine

Aquestive Therapeutics, Inc.

CEO Daniel Barber applauds FDA approval of first non-injection-based epinephrine device for anaphylaxis.
Reiterates NDA submission for Anaphylm (epinephrine) Sublingual Film in Q1 2025.
Oral allergy syndrome (OAS) challenge study completion expected late Q3 or early Q4 2024.
Full product launch of Anaphylm, if approved, targeted for end of 2025 or Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.